Levodopa-induced dyskinesia in Parkinson's disease

Journal of Neural Transmission

Volumn 112, Issue 3, 2005, Pages 359-391

  Brotchie, J M ^a   Lee, J ^a   Venderova, K ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Basal ganglia; Cannabinoid; NMDA; Opioid; Parkinson's disease; Serotonin; Synaptic plasticity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; IDAZOXAN; LEVODOPA; LISURIDE; LITHIUM; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NABILONE; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE;

BASAL GANGLION; CARDIOVASCULAR DISEASE; CHOREA; CLINICAL TRIAL; CONFERENCE PAPER; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; GABAERGIC TRANSMISSION; GLOBUS PALLIDUS; HUMAN; LEARNING DISORDER; LEVODOPA INDUCED DYSKINESIA; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVE PROJECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; SUBSTANTIA NIGRA; SYNAPSE; TACHYPHYLAXIS; TREATMENT OUTCOME;

DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, DOPAMINE;

EID: 20944432334     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0251-7     Document Type: Conference Paper

References (297)

1. Alexander GE, Crutcher MD, DeLong MR (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85: 119-146
2. Angehagen M, Ben-Menachem E, Shank R, Ronnback L, Hansson E (2004) Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem 88: 320-325
3. Aosaki T, Graybiel AM, Kimura M (1994) Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys. Science 265: 412-415
4. Arenas E, Alberch J, Marsal J (1991) Dopaminergic system mediates only delta-opiate inhibition of endogenous acetylcholine release evoked by glutamate from rat striatal slices. Neuroscience 42: 707-714
5. Artola A, Singer W (1993) Long-term depression of excitatory synaptic transmission and its relationship to long-term potentiation. Trends Neurosci 16: 480-487
6. Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, Turner RS, Woodard JL, Cole SA, McDonald WM, DeLong MR (1996) Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 40: 355-366
7. Baron MS, Vitek JL, Bakay RA, Green J, McDonald WM, Cole SA, DeLong MR (2000) Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord 15: 230-237
8. Bashir ZI, Collingridge GL (1994) An investigation of depotentiation of long-term potentiation in the CA1 region of the hippocampus. Exp Brain Res 100: 437-443
9. Bedard PJ, Di Paolo T, Falardeau P, Boucher R (1986) Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 379: 294-299
10. Bejjani BP, Arnulf I, Demeret S, Damier P, Bonnet AM, Houeto JL, Agid Y (2000) Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann Neurol 47: 655-658
11. Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM, Laurent A, Gentil M, Perret J (1994) Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 62: 76-84
12. Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P (1998) Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord 13 [Suppl 3]: 119-125
13. Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM (2003) Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 18: 267-274
14. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334: 71-76
15. Bergareche A, De La Puente E, Lopez-De Munain A, Sarasqueta C, De Arce A, Poza JJ, Marti-Masso JF (2004) Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. J Neurol 251: 340-345
16. Berney A, Vingerhoets F, Perrin A, Guex P, Villemure JG, Burkhard PR, Benkelfat C, Ghika J (2002) Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 59: 1427-1429
17. Bevan MD, Magill PJ, Terman D, Bolam JP, Wilson CJ (2002a) Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci 25: 525-531
18. Bevan MD, Magill PJ, Hallworth NE, Bolam JP, Wilson CJ (2002b) Regulation of the timing and pattern of action potential generation in rat subthalamic neurons in vitro by GABA-A IPSPs. J Neurophysiol 87: 1348-1362
19. Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2: 577-588
20. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9: 762-767
21. Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H (2004) Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 485: 159-164
22. Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57: 1829-1834
23. Blanchet P, Bedard PJ, Britton DR, Kebabian JW (1993) Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 267: 275-279
24. Blanchet PJ, Konitsiotis S, Chase TN (1997) Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 283: 794-799
25. Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13: 798-802
26. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN (1999) Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J Pharmacol Exp Ther 290: 1034-1040
27. Blanchet PJ, Calon F, Morissette M, Tahar AH, Belanger N, Samadi R, Grondin R, Gregoire L, Meltzer L, Di Paolo T, Bedard PJ (2004) Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 10: 297-304
28. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW (1997) Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 77: 309-323
29. Boraud T, Bezard E, Bioulac B, Gross CE (2001) Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124: 546-557
30. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94: 3363-3367
31. Bordet R, Ridray S, Schwartz JC, Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12: 2117-2123
32. Brotchie JM (1999) Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia. Adv Neurol 80: 71-85
33. Brotchie JM (2003) CB(1) cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 3: 54-61
34. Brown P (2003) Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord 18: 357-363
35. Brown TM, Brotchie JM, Fitzjohn SM (2003) Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci 23: 11073-11077
36. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA, Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J Neurosci 14: 5471-5484
37. Burchiel KJ, Anderson VC, Favre J, Hammerstad JP (1999) Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery 45: 1375-1382; discussion 1382-1374
38. Calabresi P, Maj R, Mercuri NB, Bernardi G (1992) Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. Neurosci Lett 142: 95-99
39. Calabresi P, Pisani A, Mercuri NB, Bernardi G (1993) Lithium treatment blocks long-term synaptic depression in the striatum. Neuron 10: 955-962
40. Calabresi P, Gubellini P, Centonze D, Sancesario G, Morello M, Giorgi M, Pisani A, Bernardi G (1999) A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci 19: 2489-2499
41. Calabresi P, Giacomini P, Centonze D, Bernardi G (2000a) Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 47: S60-S68; discussion S68-S69
42. Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, Chergui K, Svenningsson P, Fienberg AA, Greengard P (2000b) Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci 20: 8443-8451
43. Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Di Paolo T, Bedard PJ (2000) Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47: S70-S78
44. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di PT (2002a) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61: 186-196
45. Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di PT (2002b) Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26: 127-138
46. Cenci MA, Lee CS, Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10: 2694-2706
47. Centonze D, Gubellini P, Pisani A, Bernardi G, Calabresi P (2003) Dopamine, acetylcholine and nitric oxide systems interact to induce corticostriatal synaptic plasticity. Rev Neurosci 14: 207-216
48. Charpier S, Mahon S, Deniau JM (1999) In vivo induction of striatal long-term potentiation by low-frequency stimulation of the cerebral cortex. Neuroscience 91: 1209-1222
49. Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50: S17-S25
50. Chase TN, Oh JD, Blanchet PJ (1998) Neostriatal mechanisms in Parkinson's disease. Neurology 51: S30-S35
51. Chassain C, Eschalier A, Durif F (2003) Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys. Exp Neurol 182: 490-496
52. Chergui K, Bouron A, Normand E, Mulle C (2000) Functional GluR6 kainate receptors in the striatum: indirect downregulation of synaptic transmission. J Neurosci 20: 2175-2182
53. Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 13: 277-280
54. Clarke CE, Deane KH (2001) Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev CD001516
55. Clarke CE, Speller JM, Clarke JA (2000) Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev CD002261
56. Crosby NJ, Deane KH, Clarke CE (2003) Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev CD003467
57. Crossman AR (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 5: 100-108
58. Crossman AR (2000) Functional anatomy of movement disorders. J Anat 196(Pt 4): 519-525
59. Cussac D, Newman-Tancredi A, Audinot V, Nicholas J, Boutin J, Gobert A, Millan M (2000) The novel dopamine receptor partial agonist, BP897, is a potent ligand at diverse adrenergic and serotonergic receptors. Am Soc Neurosci Abstr 26: 1292
60. Daw MI, Chittajallu R, Bortolotto ZA, Dev KK, Duprat F, Henley JM, Collingridge GL, Isaac JT (2000) PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron 28: 873-886
61. De Ceballos ML, Fernandez A, Jenner P, Marsden CD (1993) Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients. Neurosci Lett 160: 163-166
62. De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 10-15
63. Dekeyne A, Iob L, Millan MJ (2003) Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907. Neuropharmacology 44: 604-615
64. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U (2001) Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16: 515-520
65. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14: 1432-1438
66. Doshi PK, Chhaya N, Bhatt MH (2002) Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 17: 1084-1085
67. Dunah AW, Standaert DG (2001) Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21: 5546-5558
68. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 57: 342-352
69. Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG (2004) Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol 65: 121-129
70. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y (1995) Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45: 1855-1858
71. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62: 381-388
72. Duty S, Henry B, Crossman AR, Brotchie JM (1998) Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp Neurol 150: 223-234
73. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 552: 113-118
74. Engber TM, Boldry RC, Kuo S, Chase TN (1992) Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 581: 261-268
75. Engber TM, Papa SM, Boldry RC, Chase TN (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5: 2586-2588
76. Facca A, Sanchez-Ramos J (1996) High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 11: 327-329
77. Ferreira JJ, Rascol O (2000) Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol 13: 431-436
78. Fienberg AA, Greengard P (2000) The DARPP-32 knockout mouse. Brain Res Brain Res Rev 31: 313-319
79. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, Cheramy A, O_Callaghan JP, Miller DB, Cole DG, Corbett R, Haile CN, Cooper DC, Onn SP, Grace AA, Ouimet CC, White FJ, Hyman SE, Surmeier DJ, Girault J, Nestler EJ, Greengard P (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281: 838-842
80. Fine J, Duff J, Chen R, Chir B, Hutchison W, Lozano AM, Lang AE (2000) Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. N Engl J Med 342: 1708-1714
81. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16: 642-650
82. Fox SH, Henry B, Hill M, Crossman A, Brotchie J (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 17: 1180-1187
83. Fox SH, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher M, Crossman A, Brotchie J (2004) Non-subtype-selective opioid receptor antagonism in the treatment of L-DOPA-induced motor complications in Parkinson's disease. Mov Disord (in press)
84. Fraix V, Pollak P, Van-Blercom N, Xie J, Krack P, Koudsie A, Benabid AL (2000) Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. Neurology 55: 1921-1923
85. Friedman A (1985) Levodopa-induced dyskinesia: clinical observations. J Neurol 232: 29-31
86. Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85: 468-471
87. Gerdeman GL, Ronesi, Lovinger DM (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5: 446-451
88. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41 [Suppl 1]: S10-S16
89. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363
90. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD (1995) Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease - the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology 117: 403-412
91. Goebel DJ, Poosch MS (1999) NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A. Brain Res Mol Brain Res 69: 164-170
92. Gomez-Mancilla B, Bedard PJ (1991) Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 259: 409-413
93. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16: 418-427
94. Gray A, McNamara I, Aziz T, Gregory R, Bain P, Wilson J, Scott R (2002) Quality of life outcomes following surgical treatment of Parkinson's disease. Mov Disord 17: 68-75
95. Gray AM, Rawls SM, Shippenberg TS, McGinty JF (1999) The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem 73: 1066-1074
96. Graybiel AM (1995) Building action repertoires: memory and learning functions of the basal ganglia. Curr Opin Neurobiol 5: 733-741
97. Graybiel AM (1998) The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem 70: 119-136
98. Graybiel AM, Canales JJ, Capper Loup C (2000) Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 23: S71-S77
99. Grondin R, Bedard PJ, Britton DR, Shiosaki K (1997) Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 49: 421-426
100. Grondin R, Doan VD, Gregoire L, Bedard PJ (1999) D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52: 771-776
101. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361: 181-186
102. Gross C, Rougier A, Guehl D, Boraud T, Julien J, Bioulac B (1997) High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. J Neurosurg 87: 491-498
103. Gross CE, Boraud T, Guehl D, Bioulac B, Bezard E (1999) From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research? Prog Neurobiol 59: 509-532
104. Gubellini P, Saulle E, Centonze D, Costa C, Tropepi D, Bernardi G, Conquet F, Calabresi P (2003) Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology 44: 8-16
105. Guillin O, Griffon N, Bezard E, Leriche L, Diaz J, Gross C, Sokoloff P (2003) Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. Eur J Pharmacol 480: 89-95
106. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2001) Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57: 2278-2282
107. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2004) Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 19: 49-53
108. Hadj-Tahar A, Grondin R, Gregoire L, Calon F, Di Paolo T, Bedard PJ (2003) New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable. Adv Neurol 91: 51-64
109. Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O (2002) Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5: 627-628
110. Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM (2004) The subthalamic nucleus in the context of movement disorders. Brain 127: 4-20
111. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (2002a) Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur J Pharmacol 451: 157-160
112. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (2002b) Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 303: 952-958
113. Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R (2000) Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287: 2262-2267
114. Heimer G, Bar Gad I, Goldberg JA, Bergman H (2002) Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine primate model of parkinsonism. J Neurosci 22: 7850-7855
115. Henry B, Crossman AR, Brotchie JM (1998) Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151: 334-342
116. Henry B, Crossman AR, Brotchie JM (1999a) Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155: 204-220
117. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM (1999b) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14: 744-753
118. Henry B, Fox SH, Crossman AR, Brotchie JM (2001) Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 171: 139-146
119. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM (2003) Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 183: 458-468
120. Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 451-460
121. Herrera-Marschitz M, Goiny M, You ZB, Meana JJ, Engidawork E, Chen Y, Rodriguez-Puertas R, Broberger C, Andersson K, Terenius L, Hokfelt T, Ungerstedt U (1998) Release of endogenous excitatory amino acids in the neostriatum of the rat under physiological and pharmacologically-induced conditions. Amino Acids 14: 197-203
122. Hikosaka O (1989) Role of basal ganglia in saccades. Rev Neurol (Paris) 145: 580-586
123. Hill MP, Brotchie JM (1999a) Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum. Br J Pharmacol 127: 275-283
124. Hill MP, Brotchie JM (1999b) The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br J Pharmacol 128: 1577-1585
125. Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H (2003) Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 18: 1301-1305
126. Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H (2004) Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 310: 386-394
127. Hiroi N, Fienberg AA, Haile CN, Alburges M, Hanson GR, Greengard P, Nestler EJ (1999) Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur J Neurosci 11: 1114-1118
128. Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M (2004) Effect of the D3 dopamine receptor partial agonist BP897 on L-dopa-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther 311: 770-777
129. Huang CC, Liang YC, Hsu KS (2001) Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses. J Biol Chem 276: 48108-48117
130. Hurley MJ, Stubbs CM, Jenner P, Marsden CD (1996a) D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 214: 75-78
131. Hurley MJ, Jolkkonen J, Stubbs CM, Jenner P, Marsden CD (1996b) Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res 709: 259-264
132. Hurley MJ, Mash DC, Jenner P (2003) Expression of cannabinoid CB(1) receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm 110: 1279-1288
133. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P (2003) 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J Neurosci 23: 9107-9115
134. Jahanshahi M, Ardouin CM, Brown RG, Rothwell JC, Obeso J, Albanese A, Rodriguez Oroz MC, Moro E, Benabid AL, Pollak P, Limousin Dowsey P (2000) The impact of deep brain stimulation on executive function in Parkinson's disease. Brain 123(Pt 6): 1142-1154
135. Jarrahian A, Watts VJ, Barker EL (2004) D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308: 880-886
136. Johansson PA, Andersson M, Andersson KE, Cenci MA (2001) Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of 1-DOPA-induced dyskinesia. Neurobiol Dis 8: 220-239
137. Kim CH, Chung HJ, Lee HK, Huganir RL (2001) Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Proc Natl Acad Sci USA 98: 11725-11730
138. Kis B, Schrag A, Ben-Shlomo Y, Klein C, Gasperi A, Spoegler F, Schoenhuber R, Pramstaller PP (2002) Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology 58: 1820-1825
139. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE (2003) Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 99: 489-495
140. Klintenberg R, Svenningsson P, Gunne L, Andren PE (2002) Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. J Neural Transm 109: 1295-1307
141. Kolomiets BP, Deniau JM, Glowinski J, Thierry AM (2003) Basal ganglia and processing of cortical information: functional interactions between trans-striatal and trans-subthalamic circuits in the substantia nigra pars reticulata. Neuroscience 117: 931-938
142. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54: 1589-1595
143. Krack P, Limousin P, Benabid AL, Pollak P (1997) Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet 350: 1676
144. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, Benabid AL (1998) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 121(Pt 3): 451-457
145. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349: 1925-1934
146. Kumar R, Lozano AM, Montgomery E, Lang AE (1998a) Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease. Mov Disord 13 [Suppl 1]: 73-82
147. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE (1998b) Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51: 850-855
148. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W (1997a) Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 337: 1036-1042
149. Lang AE, Lozano A, Tasker R, Duff J, Saint-Cyr J, Trepanier L (1997b) Neuropsychological and behavioral changes and weight gain after medial pallidotomy. Ann Neurol 41: 834-836
150. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernandez-Ruiz JJ (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14: 1827-1832
151. Lees AJ, Katzenschlager R, Head J, Ben Shlomo Y (2001) Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687-1694
152. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304: 1021-1024
153. Louis ED, Luchsinger JA, Tang MX, Mayeux R (2003) Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology 61: 24-28
154. Lovinger DM (1991) Trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) decreases synaptic excitation in rat striatal slices through a presynaptic action. Neurosci Lett 129: 17-21
155. Lovinger DM, Tyler E (1996) Synaptic transmission and modulation in the neostriatum. Int Rev Neurobiol 39: 77-111
156. Lovinger DM, Partridge JG, Tang KC (2003) Plastic control of striatal glutamatergic transmission by ensemble actions of several neurotransmitters and targets for drugs of abuse. Ann NY Acad Sci 1003: 226-240
157. Lozano AM, Lang AE (2001) Pallidotomy for Parkinson's disease. Adv Neurol 86: 413-420
158. Lozano AM, Lang AE, Galvez Jimenez N, Miyasaki J, Duff J, Hutchinson WD, Dostrovsky JO (1995) Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 346: 1383-1387
159. Luginger E, Wenning GK, Bosch S, Poewe W (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 15: 873-878
160. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15: 120-132
161. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16: 110-123
162. Luscher C, Xia H, Beattie EC, Carroll RC, von Zastrow M, Malenka RC, Nicoll RA (1999) Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron 24: 649-658
163. Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM (1995) Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 683: 102-108
164. Maneuf YP, Crossman AR, Brotchie JM (1996a) Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 22: 382-385
165. Maneuf YP, Nash JE, Crossman AR, Brotchie JM (1996b) Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308: 161-164
166. Maneuf YP, Crossman AR, Brotchie JM (1997) The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 148: 265-270
167. Manson AJ, Iakovidou E, Lees AJ (2000) Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 15: 336-337
168. Manson AJ, Katzenschlager R, Hobart J, Lees AJ (2001) High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry 70: 554-556
169. Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 17: 1235-1241
170. Manzanares J, Corchero J, Romero J, Fernandez Ruiz JJ, Ramos JA, Fuentes JA (1998) Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 55: 126-132
171. Maratos EC, Jackson MJ, Pearce RK, Jenner P (2001) Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naiive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 16: 631-641
172. Marsden CD (1998) Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs 55 [Suppl 1]: 17-22
173. Massey PV, Johnson BE, Moult PR, Auberson YP, Brown MW, Molnar E, Collingridge GL, Bashir ZI (2004) Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 24: 7821-7828
174. Matsumura M, Tremblay L, Richard H, Filion M (1995) Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 65: 59-70
175. Meco G, Fabrizio E, Di Rezze S, Alessandri A, Pratesi L (2003) Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 26: 179-181
176. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56: 1383-1386
177. Metman LV, Konitsiotis S, Chase TN (2000) Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 15: 3-8
178. Molinuevo JL, Valldeoriola F, Tolosa E, Rumia J, Valls Sole J, Roldan H, Ferrer E (2000) Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Arch Neurol 57: 983-988
179. Montastruc JL, Rascol O, Rascol A (1989) A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 52: 773-775
180. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12: 529-540
181. Morissette M, Goulet M, Grondin R, Blanchet P, Bedard PJ, Di Paolo T, Levesque D (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10: 2565-2573
182. Muriel MP, Bernard V, Levey AI, Laribi O, Abrous DN, Agid Y, Bloch B, Hirsch EC (1999) Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol 46: 103-111
183. Muriel MP, Orieux G, Hirsch EC (2002) Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. Mov Disord 17: 1174-1179
184. Navarro M, Chowen J, Rocio A, Carrera M, del Arco I, Villanua MA, Martin Y, Roberts AJ, Koob GF, de Fonseca FR (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9: 3397-3402
185. Newman DD, Rajakumar N, Flumerfelt BA, Stoessl AJ (1997) A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. Neuroreport 8: 669-672
186. Nicholson SL, Brotchie JM (2002) 5-Hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 9 [Suppl 3]: 1-6
187. Nini A, Feingold A, Slovin H, Bergman H (1995) Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. J Neurophysiol 74: 1800-1805
188. Nutt JG, Rosin AJ, Eisler T, Calne DB, Chase TN (1978) Effect of an opiate antagonist on movement disorders. Arch Neurol 35: 810-811
189. Obeso JA, Rodriguez Oroz MC, Rodriguez M, DeLong MR, Olanow CW (2000a) Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 47: S22-S32; discussion S32-S24
190. Obeso JA, Rodriguez Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW (2000b) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23: S8-S19
191. Oertel WH, Quinn NP (1997) Parkinson's disease: drug therapy. Baillieres Clin Neurol 6: 89-108
192. Ogura M, Kita H (2000) Dynorphin exerts both postsynaptic and presynaptic effects in the Globus pallidus of the rat. J Neurophysiol 83: 3366-3376
193. Oh JD, Chase TN (2002) Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 23: 133-139
194. Oh JD, Russell DS, Vaughan CL, Chase TN, Russell D (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 813: 150-159
195. Oh JD, Vaughan CL, Chase TN (1999) Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 821: 433-442
196. Oh JD, Bibbiani F, Chase TN (2002) Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 177: 557-564
197. Oh JD, Geller AI, Zhang G, Chase TN (2003) Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Res 971: 18-30
198. Oh S, Kim YH, Hann HJ, Lee HL, Choi HS, Kim HS, Ho IK (2001) Modulation of the levels of NMDA receptor subunit mRNA and the bindings of [3H]MK-801 in rat brain by chronic infusion of subtoxic dose of MK-801. Neurochem Res 26: 559-565
199. Pact V, Giduz T (1999) Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 53: 1154
200. Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39: 574-578
201. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701: 13-18
202. Partridge JG, Apparsundaram S, Gerhardt GA, Ronesi J, Lovinger DM (2002) Nicotinic acetylcholine receptors interact with dopamine in induction of striatal long-term depression. J Neurosci 22: 2541-2549
203. Patel NK, Heywood P, O'Sullivan K, McCarter R, Love S, Gill SS (2003) Unilateral subthalamotomy in the treatment of Parkinson's disease. Brain 126: 1136-1145
204. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 10: 731-740
205. Pearce RK, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13: 234-241
206. Pearce RK, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD (1999) Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology 142: 51-60
207. Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Kruger J, Jenner P (2002) The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord 17: 877-886
208. Penney JB, Young AB (1983) Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci 6: 73-94
209. Penney JB, Young AB (1986) Striatal inhomogeneities and basal ganglia function. Mov Disord 1: 3-15
210. Pentney RJ, Gratton A (1991) Effects of local delta and mu opioid receptor activation on basal and stimulated dopamine release in striatum and nucleus accumbens of rat: an in vivo electrochemical study. Neuroscience 45: 95-102
211. Perier C, Marin C, Bonastre M, Tolosa E, Hirsch EC (2002) AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa. Eur J Neurosci 16: 2236-2240
212. Piccini A, Malinow R (2002) Critical postsynaptic density 95/disc large/zonula occludens-1 interactions by glutamate receptor 1 (GluR1) and GluR2 required at different subcellular sites. J Neurosci 22: 5387-5392
213. Piccini P, Weeks RA, Brooks DJ (1997) Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 42: 720-726
214. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard R, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6: 501-506
215. Pisani A, Calabresi P, Centonze D, Bernardi G (1997) Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 120: 1007-1014
216. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, Bernardi G, Calabresi P (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106: 579-587
217. Porter RH, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64: 614-623
218. Poulsen CF, Simeone TA, Maar TE, Smith-Swintosky V, White HS, Schousboe A (2004) Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem Res 29: 275-282
219. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284: 1931-1938
220. Quinn NP (1997) Parkinson's disease: clinical features. Baillieres Clin Neurol 6: 1-13
221. Quinn NP (1998) Classification of fluctuations in patients with Parkinson's disease. Neurology 51: S25-S29
222. Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson's disease. Mov Disord 2: 73-91
223. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M (1979) Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 42: 143-150
224. Rascol O (2000) Medical treatment of levodopa-induced dyskinesias. Ann Neurol 47: S179-S188
225. Rascol O, Fabre N, Blin O, Poulik J, Sabatini U, Senard JM, Ane M, Montastruc JL, Rascol A (1994) Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 9: 437-440
226. Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S, Carter JH, Nutt JG (1999) ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 45: 736-741
227. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342: 1484-1491
228. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y (2001a) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16: 708-713
229. Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WW, Wright S (2001b) Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58: 249-254
230. Ravenscroft P, Chalon S, Brotchie JM, Crossman AR (2004) Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol 185: 36-46
231. Rawls SM, McGinty JF (2000) Delta opioid receptors regulate calcium-dependent, amphetamine-evoked glutamate levels in the rat striatum: an in vivo microdialysis study. Brain Res 861: 296-304
232. Rawls SM, McGinty JF, Terrian DM (1999) Presynaptic kappa-opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes. J Neurochem 73: 1058-1065
233. Raz A, Vaadia E, Bergman H (2000) Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. J Neurosci 20: 8559-8571
234. Raz A, Frechter-Mazar V, Feingold A, Abeles M, Vaadia E, Bergman H (2001) Activity of pallidal and striatal tonically active neurons is correlated in mptp-treated monkeys but not in normal monkeys. J Neurosci 21: RC128
235. Romito LM, Scerrati M, Contarino MF, Iacoangeli M, Bentivoglio AR, Albanese A (2003) Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up. J Neurosurg Sci 47: 119-128
236. Ruskin DN, Bergstrom DA, Tierney PL, Walters JR (2003) Correlated multisecond oscillations in firing rate in the basal ganglia: modulation by dopamine and the subthalamic nucleus. Neuroscience 117: 427-438
237. Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE (2000) Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 123(Pt 10): 2091-2108
238. Samadi P, Gregoire L, Bedard PJ (2003) Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 45: 954-963
239. Samuel M, Caputo E, Brooks DJ, Schrag A, Scaravilli T, Branston NM, Rothwell JC, Marsden CD, Thomas DG, Lees AJ, Quinn NP (1998) A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain 121(Pt 1): 59-75
240. Sanudo-Pena MC, Walker JM (1997) Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 77: 1635-1638
241. Sanudo-Pena MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65: 703-713
242. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18: 872-883
243. Schoffelmeer AN, Hogenboom F, Mulder AH (1997) Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. Br J Pharmacol 122: 520-524
244. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123(Pt 11): 2297-2305
245. Schrag A, Samuel M, Caputo E, Scaravilli T, Troyer M, Marsden CD, Thomas DG, Lees AJ, Brooks DJ, Quinn NP (1999) Unilateral pallidotomy for Parkinson's disease: results after more than 1 year. J Neurol Neurosurg Psychiatry 67: 511-517
246. Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15: 1112-1118
247. Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 73: 529-534
248. Schultz W (2002) Getting formal with dopamine and reward. Neuron 36: 241-263
249. Schultz W, Tremblay L, Hollerman JR (2003) Changes in behavior-related neuronal activity in the striatum during learning. Trends Neurosci 26: 321-328
250. Segovia G, Mora F, Crossman AR, Brotchie JM (2003) Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord 18: 138-149
251. Sevillano MD, de Pedro-Cuesta J, Duarte J, Claveria LE (2002) Field validation of a method for population screening of parkinsonism. Mov Disord 17: 258-264
252. Shi S, Hayashi Y, Esteban JA, Malinow R (2001) Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell 105: 331-343
253. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57: 2108-2111
254. Silverdale MA, Crossman AR, Brotchie JM (2002) Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Exp Neurol 174: 21-28
255. Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM (2004) Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 188: 128-138
256. Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P (2002) Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 17: 887-901
257. Spadoni F, Martella G, Martorana A, Lavaroni F, D'Angelo V, Bernardi G, Stefani A (2004) Opioid-mediated modulation of calcium currents in striatal and pallidal neurons following reserpine treatment: focus on kappa response. Synapse 51: 194-205
258. Spencer JP, Murphy KP (2000) Bi-directional changes in synaptic plasticity induced at corticostriatal synapses in vitro. Exp Brain Res 135: 497-503
259. Spencer JP, Murphy KP (2002) Activation of cyclic AMP-dependent protein kinase is required for long-term enhancement at corticostriatal synapses in rats. Neurosci Lett 329: 217-221
260. Stanford IM, Cooper AJ (1999) Presynaptic mu and delta opioid receptor modulation of GABAA IPSCs in the rat globus pallidus in vitro. J Neurosci 19: 4796-4803
261. Stefani A, Chen Q, Flores-Hernandez J, Jiao Y, Reiner A, Surmeier DJ (1998) Physiological and molecular properties of AMPA/Kainate receptors expressed by striatal medium spiny neurons. Dev Neurosci 20: 242-252
262. Stefani A, Spadoni F, Giacomini P, Lavaroni F, Bernardi G (2001) The activation of mu opioid receptors promotes a small modulation of calcium currents in rat pallidal neurons. Brain Res 897: 207-212
263. Steiner H, Gerfen CR (1998) Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 123: 60-76
264. Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125: 2058-2066
265. Sung KW, Choi S, Lovinger DM (2001) Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. J Neurophysiol 86: 2405-2412
266. Svenningsson P, Fienberg AA, Allen PB, Moine CL, Lindskog M, Fisone G, Greengard P, Fredholm BB (2000) Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32. J Neurochem 75: 248-257
267. Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K (1998) Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85: 395-403
268. Tahar AH, Blanchet PJ, Doyon J (2004) Motor-learning impairment by amantadine in healthy volunteers. Neuropsychopharmacology 29: 187-194
269. Tamma F, Rampini P, Egidi M, Caputo E, Locatelli M, Pesenti A, Chiesa V, Ardolino G, Foffani G, Meda B, Pellegrini M, Priori A (2003) Deep brain stimulation for Parkinson's disease: the experience of the Policlinico-San Paolo Group in Milan. Neurol Sci 24 [Suppl 1]: S41-S42
270. Taylor MD, De Ceballos ML, Rose S, Jenner P, Marsden CD (1992) Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4- dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur J Pharmacol 219: 183-192
271. Tel BC, Zeng BY, Cannizzaro C, Pearce RK, Rose S, Jenner P (2002) Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115: 1047-1058
272. Terman D, Rubin JE, Yew AC, Wilson CJ (2002) Activity patterns in a model for the subthalamopallidal network of the basal ganglia. J Neurosci 22: 2963-2976
273. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75: 141-143
274. Trabucchi M, Bassi S, Frattola L (1982) Effect of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy. Arch Neurol 39: 120-121
275. Trepanier LL, Kumar R, Lozano AM, Lang AE, Saint-Cyr JA (2000) Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. Brain Cogn 42: 324-347
276. Treseder SA, Jackson M, Jenner P (2000a) The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates. Br J Pharmacol 129: 1355-1364
277. Treseder SA, Smith LA, Jenner P (2000b) Endogenous dopaminergic tone and dopamine agonist action. Mov Disord 15: 804-812
278. van Kampen JM, Stoessl AJ (2003) Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 116: 307-314
279. Varma TR, Fox SH, Eldridge PR, Littlechild P, Byrne P, Forster A, Marshall A, Cameron H, Mclver K, Fletcher N, Steiger M (2003) Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. J Neurol Neurosurg Psychiatry 74: 170-174
280. Vergara R, Rick C, Hernandez Lopez S, Laville JA, Guzman JN, Galarraga E, Surmeier DJ, Bargas J (2003) Spontaneous voltage oscillations in striatal projection neurons in a rat corticostriatal slice. J Physiol 553: 169-182
281. Verhagen-Metman L, Del-Dotto P, Natte R, van-den-Munckhof P, Chase TN (1998a) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51: 203-206
282. Verhagen-Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN (1998b) A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 13: 414-417
283. Verhagen-Metman L, Del-Dotto P, van-den-Munckhof P, Fang J, Mouradian MM, Chase TN (1998c) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50: 1323-1326
284. Vigano D, Grazia-Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, Parolaro D (2003) Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 28: 1160-1167
285. Vitek JL, Giroux M (2000) Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 47: S131-S140
286. Vitek JL, Bakay RA, Freeman A, Evatt M, Green J, McDonald W, Haber M, Barnhart H, Wahlay N, Triche S, Mewes K, Chockkan V, Zhang JY, DeLong MR (2003) Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 53: 558-569
287. Waelti P, Dickinson A, Schultz W (2001) Dopamine responses comply with basic assumptions of formal learning theory. Nature 412: 43-48
288. Wagner ML, Fedak MN, Sage JI, Mark MH (1996) Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann Clin Lab Sci 26: 389-395
289. Wallmichrath I, Szabo B (2002) Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn Schmiedebergs Arch Pharmacol 365: 326-334
290. Westin JE, Andersson M, Lundblad M, Cenci MA (2001) Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14: 1171-1176
291. Wichmann T, DeLong MR (1999) Oscillations in the basal ganglia. Nature 400: 621-622
292. Wichmann T, DeLong MR (2003) Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 91: 9-18
293. Wichmann T, Bergman H, Starr PA, Subramanian T, Watts RL, DeLong MR (1999) Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Exp Brain Res 125: 397-409
294. Williams D, Kuhn A, Kupsch A, Tijssen M, van Bruggen G, Speelman H, Hotton G, Yarrow K, Brown P (2003) Behavioural cues are associated with modulations of synchronous oscillations in the human subthalamic nucleus. Brain 126: 1975-1985
295. Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10: 165-186
296. You ZB, Herrera-Marschitz M, Terenius L (1999) Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J Pharmacol Exp Ther 290: 1307-1315
297. Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P (1999) Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett 276: 71-74